|
May 3
|
Amgen Stock Is Having Its Best Day Since 2009. Why Wall Street Is Excited About Its Weight-Loss Drug.
|
|
May 3
|
US STOCKS-Wall St gains after soft jobs data allays rate jitters
|
|
May 3
|
Amgen surges over confidence in early obesity drug results
|
|
May 3
|
These Two Stocks Are Driving the Dow Friday
|
|
May 3
|
Amgen Soars as CEO Touts Experimental Obesity Drug Progress
|
|
May 3
|
Amgen upgraded, Peloton downgraded: Wall Street's top analyst calls
|
|
Jan 15
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jan 15
|
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
|
|
Jan 15
|
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca
|
|
Jan 12
|
Dow Jones Falls On Cool Inflation Data; Tesla Stock Slides Despite Cathie Wood Buys
|
|
Jan 12
|
FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts
|
|
Jan 11
|
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
|
|
Jan 11
|
UPDATE 1-Weight loss drug windfall attracts pharma companies
|
|
Jan 11
|
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
|
|
Jan 11
|
Drugmakers plot way into obesity market with deals and development
|
|
Jan 10
|
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
|
|
Jan 9
|
Dow Jones Futures Fall: Magnificent Seven Stocks Rally; Nvidia Breaks Out Past Buy Point
|
|
Jan 2
|
FDA ends busy year with three drug rejections
|
|
Dec 29
|
Amgen (AMGN) Stock Moves -0.15%: What You Should Know
|
|
Dec 29
|
Neurological and obesity drugs will be prevalent in 2024
|